% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Rautajoki:181272,
      author       = {K. J. Rautajoki and S. Jaatinen and A. M. Tiihonen and M.
                      Annala and E. M. Vuorinen and A. Kivinen and M. J. Rauhala
                      and K. Maass$^*$ and K. Pajtler$^*$ and O. Yli-Harja and P.
                      Helén and J. Haapasalo and H. Haapasalo and W. Zhang and M.
                      Nykter},
      title        = {{PTPRD} and {CNTNAP}2 as markers of tumor aggressiveness in
                      oligodendrogliomas.},
      journal      = {Scientific reports},
      volume       = {12},
      number       = {1},
      issn         = {2045-2322},
      address      = {[London]},
      publisher    = {Macmillan Publishers Limited, part of Springer Nature},
      reportid     = {DKFZ-2022-01915},
      pages        = {14083},
      year         = {2022},
      abstract     = {Oligodendrogliomas are typically associated with the most
                      favorable prognosis among diffuse gliomas. However, many of
                      the tumors progress, eventually leading to patient death. To
                      characterize the changes associated with oligodendroglioma
                      recurrence and progression, we analyzed two recurrent
                      oligodendroglioma tumors upon diagnosis and after tumor
                      relapse based on whole-genome and RNA sequencing. Relapsed
                      tumors were diagnosed as glioblastomas with an
                      oligodendroglioma component before the World Health
                      Organization classification update in 2016. Both patients
                      died within 12 months after relapse. One patient carried an
                      inactivating POLE mutation leading to a clearly hypermutated
                      progressed tumor. Strikingly, both relapsed tumors carried
                      focal chromosomal rearrangements in PTPRD and CNTNAP2 genes
                      with associated decreased gene expression. TP53 mutation was
                      also detected in both patients after tumor relapse. In The
                      Cancer Genome Atlas (TCGA) diffuse glioma cohort, PTPRD and
                      CNTNAP2 expression decreased by tumor grade in
                      oligodendrogliomas and PTPRD expression also in IDH-mutant
                      astrocytomas. Low expression of the genes was associated
                      with poor overall survival. Our analysis provides
                      information about aggressive oligodendrogliomas with worse
                      prognosis and suggests that PTPRD and CNTNAP2 expression
                      could represent an informative marker for their
                      stratification.},
      cin          = {B062 / HD01},
      ddc          = {600},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:35982066},
      doi          = {10.1038/s41598-022-14977-2},
      url          = {https://inrepo02.dkfz.de/record/181272},
}